Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

2cureX AB (Nasdaq First North: 2CUREX)

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor and the treatment to which the patient is resistant. Immediately after the test, the patient can be offered the selected treatment. IndiTreat® is presently being introduced into the European market. The aspiration is that IndiTreat® becomes a standard Functional Precision Medicine tool for cancer patients. The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol: “2CUREX”). *

 

Period Start 2021-01-28 existent
  Group 2cureX (Group)
Product Industry pharmacodiagnostic test (PDx)
     
Region Region Sweden_oo
  Country Sweden
  City n. a. 
    Address record changed: 2021-04-08
     
Basic data Employees n. a.
     
    * Document for �About Section�: 2cureX AB. (1/28/21). "Press Release: 2cureX Appoints Kenneth Graabek Johansen, an Experienced Business and Financial Executive, as New CFO". Copenhagen.
     
   
Record changed: 2021-06-05

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for 2cureX (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px




» top